Market Intelligence, Clinical Progress, and High-Purity Reagents for Hemophilia and Pro-Coagulant Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TFPI drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TFPI Full-Length Protein (HEK293, >95% purity, Endotoxin <1EU/µg, native glycosylation). Also available with common mutation rs5940 (VAR_012004). | View TFPI Products |
| Domain Antigen | TFPI Kunitz Domain 2 (K2) Protein – FXa-binding interface; also K1 and K3 for epitope binning. | View TFPI Products |
| Gene Delivery | TFPI Promise-ORF / Lentivirus – full-length ORF for stable overexpression in CHO or HEK293. | View TFPI Products |
| Benchmark Ab | Anti-TFPI (Sequences of Marstacimab and Concizumab) – recombinant IgG4 positive controls for assay standardization. | View TFPI Products |
| Validator | TFPI siRNA Set – for knockdown verification and specificity controls. | View TFPI Products |
| Related Target | Tissue Factor (F3) – primary cofactor in TF-FVIIa complex regulated by TFPI. | View F3 Products |
| Related Target | Coagulation Factor X (F10) – protease inhibited by TFPI-K2; downstream readout for efficacy. | View F10 Products |
| Related Target | Coagulation Factor VII (F7) – component of TF-FVIIa complex inhibited by TFPI-K1. | View F7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species Cross-Reactivity (Human/Cyno/Mouse) | Ortholog protein panel (Human, Cynomolgus, Mouse) with sequence-verified Kunitz domains (>95% purity). |
| Domain-Specific Epitope Mapping (K1 vs K2 vs K3) | Modular Kunitz domain antigens (K1, K2, K3) strictly purified; theoretical MW confirmed by mass spec. |
| Functional Activity Validation | High-purity TFPI for FXa inhibition assays; full-length ECD-Fc for complex reconstitution. |
| Isoform Specificity / Off-target | TFPI-2 protein for counter-screening; TFPI-specific siRNA for target engagement verification. |
Live TFPI R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The anti-TFPI therapeutic class represents a paradigm shift in hemophilia care, transitioning from intravenous bypass agents to subcutaneously administered inhibitors of the natural anticoagulant pathway. With recent regulatory approvals of Marstacimab and late-stage pipeline advances of Concizumab, the competitive landscape is intensifying around epitope specificity (Kunitz Domain 2 versus Domain 1) and half-life extension technologies. The next wave of R&D targets expansion into hemophilia A/B without inhibitors, optimization of thrombotic safety margins, and potential combination with gene therapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-TFPI mAb | Pfizer (Marstacimab), Novo Nordisk (Concizumab) | Hemophilia A/B with or without inhibitors | High-affinity binding to Kunitz Domain 2; cross-species panel required for toxicology. |
| Sub-Q mAb | Sanofi (SAR444245), Bayer (BAY 2599023) | Hemophilia prophylaxis | High-concentration stability assays; viscosity testing requires pure antigen standards. |
| Bispecific Antibody | Preclinical/Discovery pipelines | Hemophilia A/B | Heterodimer validation against TFPI and secondary target; dual binding affinity confirmation. |
| RNAi / ASO / Small Molecule | Early discovery (Bayer historical) | Refractory bleeding disorders | Knockdown validation; selectivity against WT vs mutant TFPI (e.g., rs5940). |
Conclusion
TarMart delivers an integrated reagent ecosystem spanning full-length TFPI, Kunitz domain truncations, multi-species orthologs, clinical benchmark antibodies, and gene delivery tools to support every stage of TFPI-targeted drug discovery from early screening to preclinical safety evaluation.